(Total Views: 1149)
Posted On: 07/07/2020 8:31:24 AM
Post# of 154115
New article in SA, read on 
https://seekingalpha.com/article/4357271-anti...idminus-19
The likelihood appears slim of an adequately effective and widely available vaccine being in commercial use before H2 2021.
Demonstration of the production of antibodies against SARS-Cov-2 is certainly no guarantee that adequate protection against COVID-19 will be forthcoming.
Non-vaccine antiviral agents hold greater promise than vaccines for the management of COVID-19.
Press releases from BioCryst Pharmaceuticals and CytoDyn about the anti-COVID efficacy of galidesivir and leronlimab, respectively, may be imminent.
If results for galidesivir and leronlimab are positive, then July increases in share price for BioCryst and CytoDyn may be to well above the $10 mark.
https://seekingalpha.com/article/4357271-anti...idminus-19
The likelihood appears slim of an adequately effective and widely available vaccine being in commercial use before H2 2021.
Demonstration of the production of antibodies against SARS-Cov-2 is certainly no guarantee that adequate protection against COVID-19 will be forthcoming.
Non-vaccine antiviral agents hold greater promise than vaccines for the management of COVID-19.
Press releases from BioCryst Pharmaceuticals and CytoDyn about the anti-COVID efficacy of galidesivir and leronlimab, respectively, may be imminent.
If results for galidesivir and leronlimab are positive, then July increases in share price for BioCryst and CytoDyn may be to well above the $10 mark.
(14)
(0)
